Human MUC1 mucin: A multifaceted glycoprotein

International Journal of Biological Markers

Volumn 15, Issue 4, 2000, Pages 343-356

  Von Mensdorff Pouilly, S ^a   Snijdewint, F G M ^a   Verstraeten, A A ^a   Verheijen, R H M ^a   Kenemans, P ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cancer; Glycopeptides; Immunotherapy; MUC1

Indexed keywords

BCG VACCINE; CANCER VACCINE; GANGLIOSIDE GM2; KEYHOLE LIMPET HEMOCYANIN; MANNAN; MUCIN; PEPTIDE ANTIBODY; PHOSPHORYL LIPID A; QS 21; THERATOPE; VACCINIA VACCINE;

ANOREXIA; ANTIGEN RECOGNITION; CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL ADHESION; CELL STRAIN MCF 7; CELLULAR IMMUNITY; CHILL; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; DOSE RESPONSE; DRUG FEVER; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; MALAISE; METASTASIS; NAUSEA AND VOMITING; NONHUMAN; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; RIGOR;

EID: 0034522603     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460080001500413     Document Type: Conference Paper

References (142)

1. Mucin gene structure and expression: Protection vs. adhesion
2. Mucin-type glycoproteins
3. Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: Production and reaction with cells in culture
4. International workshop on monoclonal antibodies and breast cancer
5. Second international workshop on monoclonal antibodies and breast cancer
6. Report on the first international workshop on carcinoma associated mucins
7. Summary report on the ISOBM TD-4 workshop: Analysis of 56 monoclonal antibodies against the MUC1 mucin
8. Tissue and tumor distribution of human polymorphic epithelial mucin
9. Ultrastructural localization of epithelial mucin core proteins in colorectal tissues
10. MUC1 expression in hematopoietic tissues
11. Expression of MUC-1 epitopes on normal bone marrow: Implications for the detection of micrometastatic tumor cells
12. Expression of MUC1 mucin on activated human T-cells: Implications for a role of MUC1 in normal immune regulation
13. Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient
14. Epithelial membrane antigen in hematolymphoid neoplasms: A review
15. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors
16. Production of monoclonal antibodies against human epithelial membrane antigen for use in diagnostic immunocytochemistry
17. MAM-6, a carcinoma associated marker: Preliminary characterization and detection in sera of breast cancer patients
18. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats
19. Episialin, a carcinoma associated mucin, is generated by a polymorphic gene encoding splice variants with alternative amino termini
20. The epithelial mucin, MUC1, of milk, mammary gland and other tissues
21. Spatial and temporal expression of an epithelial mucin, Muc-1, during mouse development
22. Immunohistochemical expression of tumor associated glycoprotein and polymorphic epithelial mucin in the human endometrium during the menstrual cycle
23. The polymorphic epithelial mucin MUC1 in human endometrium is regulated with maximal expression in the implantation phase
24. The endometrial cell surface and implantation: Expression of the polymorphic mucin MUC-1 and adhesion molecules during the endometrial cycle
25. Regional specialization of the cell membrane-associated, polymorphic mucin (MUC1) in human uterine epithelia
26. Oligosaccharide differences in the DF3 sialomucin antigen from normal human milk and the BT-20 human breast carcinoma cell line
27. Effect of modification of carbohydrate side chains on the reactivity of antibodies with core-protein epitopes of the MUC1 gene product
28. Comparison of circulating CA 15.3 and carcinoembryonic antigen levels in patients with breast cancer
29. Involvement of the cell-surface bound mucin, episialin/MUC1, in progression of human carcinomas
30. Clinical and technical evaluation of ACS™BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assays
31. MUC1 mucin assays for monitoring therapy in metastatic breast cancer
32. Distinct sub-populations of carcinoma-associated MUC1 mucins as detected by the monoclonal antibody 9H8 and antibodies against the sialyl-Lewis a and sialyl-Lewis x epitopes in the circulation of breast cancer patients
33. MUC1 and cancer
34. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin
35. Immunological and structural features of the protein core of human polymorphic epithelial mucin
36. Studies on the order and site specificity of GalNAc transfer to MUC1 tandem repeats by UDP GalNAc: Polypeptide N-acetylgalactosaminyltransferase from milk or mammary carcinoma cells
37. Localization of O-glycosylation sites on glycopeptide fragments from lactation associated MUC1 - All putative sites within the tandem repeat are glycosylation targets in vivo
38. Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors
39. Biophysical characterization of one-, two-, and three-tandem repeats of human mucin (muc-1) protein core
40. Structure of a tumor associated antigen containing a tandemly repeated immunodominant epitope
41. Crystal structure at 1.95 angstrom resolution of the breast tumour-specific antibody SM3 complexed with its peptide epitope reveals novel hypervariable loop recognition
42. The hypervariable gene locus PUM, which codes for the tumor-associated epithelial mucins, is located on chromosome 1 within the region 1q21-24
43. Structure and expression of the human polymorphic epithelial mucin gene: An expressed VNTR unit
44. Determination of apical membrane polarity in mammary epithelial cell cultures: The role of cell-cell, cell substratum, and membrane-cytoskeleton interactions
45. Molecular cloning and analysis of the mouse homologue of the tumor-associated mucin, MUC1, reveals conservation of potential O-glycosylation sites, transmembrane, and cytoplasmic domains and a loss of minisatellite-like polymorphism
46. Loss and gain of distinct regions of chromosome 1q in primary breast cancer
47. A gene dosage effect is responsible for high overexpression of the MUC1 gene observed in human breast tumors
48. Cell membrane-associated mucins and their adhesion-modulating property
49. The epithelial mucin MUC1 contains at least two discrete signals specifying membrane localization in cells
50. Cell-associated episialin is a complex containing two proteins derived from a common precursor
51. Characterization and molecular cloning of a novel MUC1 protein, devoid of tandem repeats, expressed in human breast cancer tissue
52. Tyrosine phosphorylation of the MUC1 breast cancer membrane proteins. Cytokine receptor-like proteins
53. MUC1 isoform specific monoclonal antibody 6E6/2 detects preferential expression of the novel MUC1/Y protein in breast and ovarian cancer
54. Association of the DF3/MUC1 breast cancer antigen with Grb2 and the Sos/Ras exchange protein
55. Isolation and characterisation of mucin-like glycoprotein in human milk fat globule membrane
56. MUC 1: The polymorphic appearance of a human mucin
57. Substrate specificities of three members of the human UDP-N-acetyl α-D-galactosamine: Polypeptide N-acetylgalactosaminyltransferase family, GalNac-T1, -T2, and -T3
58. Cloning of a human UDP-N-acetyl-alpha-D galactosamine-polypeptide N-acetyl-galactosaminyltransferase that complements other GalNAc-transferases in complete O-glycosylation of the MUC1 tandem repeat
59. Structure of neutral O-linked polylactosaminoglycans on human skim milk mucins. A novel type of linearly extended poly-N-acetyllactosamine backbones with Galbeta(1-4)GlcNAc beta(l-6) repeating units
60. Structures of acidic O-linked polylactosaminoglycans on human skim milk mucins
61. Dynamic epigenetic regulation of initial O-glycosylation by UDP-N-acetyl-galactosamine: Peptide N acetylgalactosaminyltransferases - Site-specific glycosylation of MUC1 repeat peptide influences the substrate qualities at adjacent orw distant Ser/Thr positions
62. Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells
63. A transfected sialyltransferase that is elevated in breast cancer and localizes to the medial/trans-Golgi apparatus inhibits the development of core-2 based O-glycans
64. High density O-glycosylation on tandem repeat peptide from secretory MUC1 of T47D breast cancer cells
65. T and Tn pancarcinoma markers: Autoantigenic adhesion molecules in pathogenesis, prebiopsy carcinoma-detection, and long-term breast carcinoma immunotherapy
66. Carbohydrate vaccines that induce antibodies against cancer. 1. Rationale
67. Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future plans
68. Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens
69. Approaches to augmenting the immunogenicity of melanoma gangliosides: From whole melanoma cells to ganglioside-KLH conjugate vaccines
70. Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2-KLH is increased by IgG antibodies
71. Pre immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy
72. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine
73. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components
74. Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction
75. Suppression of cellular aggregation by high levels of episialin
76. Decreased MUC1 expression induces E-cadherin-mediated cell adhesion of breast cancer cell lines
77. Dissecting tumor cell invasion: Epithelial cells acquire invasive properties after the loss of uvomorulin mediated cell-cell adhesion
78. Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours
79. E selectin binding by pancreatic tumor cells is inhibited by cancer sera
80. Secreted MUC1 mucins lacking their cytoplasmic part and carrying sialyl-Lewis a and x epitopes from a tumour cell line and sera of colon carcinoma patients can inhibit HL-60 leukocyte adhesion to E selectin-expressing endothelial cells
81. The breast mucin MUC1 as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer
82. Macrophage-tumour cell interactions: Identification of MUC1 on breast cancer cells as potential counter-receptors for the macrophage-restricted receptor, sialoadhesin
83. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma
84. The origin and function of tumor-associated macrophages
85. The biological role of mucins in cellular interactions and immune regulation - Prospects for cancer immunotherapy
86. Immunosuppressive factors in human cancer
87. MUC1 synthetic peptide inhibition of intercellular adhesion molecule-1 and MUC1 binding requires six tandem repeats
88. Adhesion receptors of the immune system
89. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2
90. Soluble MUC1 secreted by human epithelial cancer cells mediate immune suppression by blocking T-cell activation
91. Cellular and humoral responses to MUC1 mucin and tandem-repeat peptides in ovarian cancer patients and controls
92. Lack of evidence for an immunosuppressive role for MUC1
93. Specific, major histocompatability complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells
94. Antigen specific, MHC-unrestricted T cells
95. MUC-1 epithelial tumor mucin-based immunity and cancer vaccines
96. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients
97. Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women
98. Detection of a circulating antibody against a peptide epitope on a mucin core protein, MUC1, in ulcerative colitis
99. Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer
100. Human B-cell immune response to the polymorphic epithelial mucin
101. Human antibodies against the polymorphic epithelial mucin in ovarian cancer patients recognise a novel sequence in the tandem repeat region
102. Isolation of MUC1-primed B lymphocytes from tumor draining lymph nodes using immunomagnetic beads
103. Polymorphic epithelial mucin (MUC-1) containing circulating immune complexes in carcinoma patients
104. An enzyme-linked immunosorbent assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUC1)
105. 'Epitope fingerprinting' using overlapping 20-mer peptides of the MUC1 tandem repeat sequence
106. Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma
107. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein
108. Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21
109. Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and N-acetylgalactosamine (GalNAc) peptides
110. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin (MUC1)
111. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells
112. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides
113. Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA
114. Does pregnancy immunize against breast cancer?
115. Cytotoxic T lymphocytes in mice immunized against human MUC1 are MHC restricted
116. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen
117. In vitro induction of MUC-1 peptide-specific type 1 T lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors
118. Identification of an HLA-A11 restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin
119. Identification of HLAA-A2 restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies
120. Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken up by dendritic cells
121. Carbohydrate recognition on MUC I-expressing targets enhances cytotoxicity of a T cell subpopulation
122. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine
123. MUC1-based immunogens for tumor therapy: Development of murine model systems
124. Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia virus expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7
125. Intramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1 expressing syngeneic mouse tumour cells
126. Vaccinia virus MUC1 immunization of mice: Immune response and protection against the growth of murine tumors bearing the MUC1 antigen
127. Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses
128. Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice
129. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model
130. Passively transferred anti-MUC1 antibodies cause neither autoimmune disorders nor immunity against transplanted tumors in MUC1 transgenic mice
131. Expression of B7.1 in a MUC1-expressing mouse mammary epithelial tumour cell line inhibits tumorigenicity but does not induce autoimmunity in MUC1 transgenic mice
132. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunised with fusions of dendritic cells and carcinoma cells
133. Induction of human breast cancer-specific antibody responses in cynomolgus monkeys by a murine monoclonal anti-idiotype antibody
134. Induction of humoral and cellular responses in cynomolgus monkeys immunised with mannan-human MUC1 conjugates
135. Induction of cellular immunity in chimpanzees to human tumor-associated antigen mucin by vaccination with MUC-I cDNA-transfected Epstein Barr virus-immortalized autologous B cells
136. Chimpanzee dendritic cells derived in vitro from blood monocytes and pulsed with antigen elicit specific immune responses in vivo
137. Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses
138. Phase I study of synthetic MUC1 peptides in breast cancer
139. A phase I trial of a synthetic mucin peptide vaccine
140. Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide
141. Vaccination of high risk breast cancer patients with Mucin-1 keyhole limpet hemocyanin conjugate plus QS-21
142. A recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in breast cancer patients